Hims & Hers Health, Inc. (NYSE:HIMS) Shares Sold by Penserra Capital Management LLC

Penserra Capital Management LLC lowered its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 36.2% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 183,357 shares of the company's stock after selling 104,244 shares during the period. Penserra Capital Management LLC owned approximately 0.08% of Hims & Hers Health worth $5,418,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in HIMS. SlateStone Wealth LLC increased its position in shares of Hims & Hers Health by 4.0% in the fourth quarter. SlateStone Wealth LLC now owns 10,640 shares of the company's stock worth $257,000 after acquiring an additional 413 shares in the last quarter. Blume Capital Management Inc. lifted its holdings in shares of Hims & Hers Health by 100.0% during the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after acquiring an additional 600 shares in the last quarter. Summit Investment Advisors Inc. boosted its position in Hims & Hers Health by 3.3% during the 4th quarter. Summit Investment Advisors Inc. now owns 19,853 shares of the company's stock worth $480,000 after purchasing an additional 628 shares during the period. Cim LLC increased its holdings in Hims & Hers Health by 1.0% in the 4th quarter. Cim LLC now owns 71,869 shares of the company's stock valued at $1,738,000 after purchasing an additional 694 shares in the last quarter. Finally, Harbour Investments Inc. raised its position in Hims & Hers Health by 18.8% in the fourth quarter. Harbour Investments Inc. now owns 5,269 shares of the company's stock valued at $127,000 after purchasing an additional 833 shares during the period. Institutional investors and hedge funds own 63.52% of the company's stock.

Insider Activity

In other Hims & Hers Health news, CEO Andrew Dudum sold 128,127 shares of the business's stock in a transaction dated Friday, May 16th. The shares were sold at an average price of $58.40, for a total transaction of $7,482,616.80. Following the completion of the transaction, the chief executive officer directly owned 89,311 shares of the company's stock, valued at $5,215,762.40. The trade was a 58.93% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Melissa Baird sold 33,337 shares of Hims & Hers Health stock in a transaction dated Wednesday, April 9th. The shares were sold at an average price of $27.32, for a total transaction of $910,766.84. Following the sale, the chief operating officer owned 805,083 shares in the company, valued at approximately $21,994,867.56. This represents a 3.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 692,006 shares of company stock valued at $34,857,872. 13.71% of the stock is currently owned by company insiders.

Hims & Hers Health Stock Performance

Shares of HIMS stock traded up $0.36 during trading hours on Monday, hitting $48.34. 27,287,587 shares of the company were exchanged, compared to its average volume of 23,484,435. The stock has a market capitalization of $10.82 billion, a price-to-earnings ratio of 70.06, a P/E/G ratio of 1.76 and a beta of 2.02. Hims & Hers Health, Inc. has a one year low of $13.47 and a one year high of $72.98. The business's 50-day simple moving average is $52.23 and its two-hundred day simple moving average is $40.38.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its earnings results on Monday, May 5th. The company reported $0.20 EPS for the quarter, topping analysts' consensus estimates of $0.12 by $0.08. Hims & Hers Health had a return on equity of 22.75% and a net margin of 9.24%. The company had revenue of $586.01 million for the quarter, compared to the consensus estimate of $535.21 million. During the same quarter last year, the business posted $0.05 EPS. Hims & Hers Health's quarterly revenue was up 110.7% compared to the same quarter last year. As a group, analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Analyst Ratings Changes

HIMS has been the subject of a number of recent research reports. UBS Group set a $30.00 target price on Hims & Hers Health in a research note on Monday, June 23rd. Wall Street Zen raised shares of Hims & Hers Health from a "hold" rating to a "buy" rating in a research report on Sunday, June 15th. Piper Sandler reissued a "neutral" rating and set a $39.00 target price (up from $35.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Citigroup restated a "sell" rating on shares of Hims & Hers Health in a research note on Monday, June 23rd. Finally, TD Cowen downgraded shares of Hims & Hers Health from a "buy" rating to a "hold" rating and dropped their price target for the stock from $44.00 to $30.00 in a research note on Tuesday, April 29th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat, Hims & Hers Health presently has a consensus rating of "Hold" and a consensus target price of $39.58.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.